IPM Take
Hypertension is usually treated as a numbers game: measure blood pressure, add medicines, escalate if control fails. But resistant hypertension should force a different question: what if the wrong problem is being treated? Primary aldosteronism is a common and underdiagnosed cause of secondary hypertension, yet many patients are never properly screened or subtyped. Pentixapharm’s Phase 3 PANDA programme is interesting because it shifts the story from treatment escalation to diagnostic precision. If imaging can help identify the biology behind resistant hypertension, then personalised cardiology moves from rare disease into one of the world’s most common cardiovascular conditions.
Executive Summary
Pentixapharm Holding AG announced on 9 June 2026 that the U.S. Food and Drug Administration cleared its Investigational New Drug application for the Phase 3 PANDA study of a CXCR4-targeted cardiovascular diagnostic programme. The study will evaluate a PET/CT imaging approach in treatment-resistant hypertension with underlying primary aldosteronism. Primary aldosteronism is a major cause of secondary hypertension and is associated with increased cardiovascular and renal risk, but it remains underdiagnosed. Current diagnostic pathways can involve biochemical screening, adrenal imaging and adrenal vein sampling, with treatment depending on whether aldosterone excess is unilateral or bilateral. The PANDA programme signals a possible move toward more precise, non-invasive disease subtyping in hypertension. For IPM, the bigger question is whether health systems are ready to diagnose the cause of resistant hypertension before simply adding another medication.
Why it matters
- Regulators: The programme may test how advanced imaging evidence can support a regulatory pathway for cardiovascular diagnostic stratification.
- Clinicians: Could eventually offer another tool for identifying patients whose resistant hypertension is driven by primary aldosteronism biology.
- Diagnostics / imaging providers: PET/CT-based stratification would require specialist imaging capacity, referral protocols and interpretation expertise.
- Payers: Reimbursement decisions would need to assess whether earlier and more accurate subtyping reduces long-term cardiovascular, renal and procedural costs.
- Patients: Better diagnosis could help some patients move from years of uncontrolled blood pressure to targeted treatment based on the underlying cause.
Most hypertension care still follows a familiar script.
Measure blood pressure. Start treatment. Add another medicine. Increase the dose. Add another medicine again.
For many patients, that works.
For others, it does not.
Treatment-resistant hypertension is often treated as a failure of control. But sometimes it is a failure of diagnosis.
That is why the FDA clearance of Pentixapharm’s IND for the Phase 3 PANDA study is worth watching.
On 9 June 2026, Pentixapharm announced that the U.S. Food and Drug Administration had cleared its Investigational New Drug application for a Phase 3 study of its CXCR4-targeted cardiovascular diagnostic programme. The U.S.-focused, multicentre PANDA study will evaluate a PET/CT imaging approach for patient stratification in treatment-resistant hypertension with underlying primary aldosteronism.
This is not a drug approval.
It is not yet a clinical practice change.
But it is a clear signal that hypertension is moving into a more precise diagnostic era.
Primary aldosteronism is one of the most important hidden causes of high blood pressure. It occurs when the adrenal glands produce too much aldosterone, a hormone that regulates sodium, potassium and fluid balance. Excess aldosterone can drive hypertension, worsen cardiovascular risk and damage the kidneys.
The condition is not rare.
It is widely recognised as a leading cause of secondary hypertension and is especially relevant in patients with resistant hypertension. Yet many patients are never diagnosed. Some are treated for years as if they have ordinary essential hypertension, while the underlying hormonal driver remains untouched.
That matters because primary aldosteronism is not just another label.
Treatment can differ depending on the biology.
Some patients have unilateral aldosterone excess, where one adrenal gland is mainly responsible. These patients may be candidates for adrenalectomy. Others have bilateral disease and are usually treated medically, often with mineralocorticoid receptor antagonists such as spironolactone.
The problem is getting patients to the right diagnosis.
Current pathways can include aldosterone-renin testing, confirmatory testing, adrenal CT and adrenal vein sampling. In practice, this can be slow, uneven and specialist-dependent. Adrenal vein sampling is technically demanding and not universally available. Many patients never even reach that stage because screening is not performed consistently.
This is where Pentixapharm’s diagnostic concept becomes policy-relevant.
The company’s programme uses a CXCR4-targeted radiodiagnostic approach, intended to visualise disease biology through PET/CT imaging. According to the company, the aim is to support non-invasive assessment and patient stratification in treatment-resistant hypertension with underlying primary aldosteronism.
If successful, this kind of approach could help answer a difficult clinical question: which patients have a treatable biological subtype of hypertension, and what treatment pathway should follow?
That is personalised medicine in a very practical form.
Not genomics for the few.
Not an ultra-rare disease pathway.
But a potential diagnostic shift inside one of the most common cardiovascular problems in the world.
The implications are significant.
For clinicians, better subtyping could reduce years of trial-and-error escalation. For patients, it could mean being treated for the cause of hypertension rather than only the blood pressure number. For payers, the value case would depend on whether improved diagnosis prevents strokes, heart failure, atrial fibrillation, kidney disease and avoidable long-term medication burden.
For hospitals, the challenge would be capacity.
PET/CT imaging is not a primary care test. It requires infrastructure, radiotracers, trained personnel, referral criteria and reimbursement. If this type of diagnostic pathway advances, health systems will need to decide who qualifies. Treatment-resistant hypertension is common, but advanced imaging cannot simply be offered to everyone with high blood pressure.
That means eligibility rules will matter.
Will testing be limited to patients with confirmed resistant hypertension? Those with abnormal aldosterone-renin ratios? Those being considered for surgery? Those in specialist hypertension clinics? Those with high cardiovascular risk?
These decisions will determine whether the innovation becomes useful or inaccessible.
There is also an equity risk.
Patients already connected to specialist cardiovascular or endocrine centres may benefit first. Patients in primary care, rural areas or fragmented health systems may continue to be treated with repeated medication escalation without ever being investigated for an underlying cause.
That is the uncomfortable part of precision medicine.
The technology may become more precise while the system remains blunt.
For IPM, the PANDA study is a strong signal because it reframes hypertension. It suggests that the next breakthrough may not be another tablet. It may be the ability to find the patients whose blood pressure has a specific, treatable biological driver.
If that happens, resistant hypertension stops being a dead end.
It becomes a diagnostic challenge.
And health systems will need to prove they can solve it.
